GOG-9924

Terminated

Return to Protocol Table

A Phase I Pharmacokinetic Study of Intraperitoneal CTEP-Supplied Agent Bortezomib (PS-341, NSC 681239, IND# 58443) and Carboplatin (NSC# 241240) in Patients with Persistent or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Principal Investigator

Don Dizon

Status

Terminated

Open to Accrual

April 5, 2010

Closed to Accrual & Treatment

April 5, 2010

Closed to Accrual & Treatment

July 12, 2014

Complete

July 12, 2014

Terminated

January 27, 2018


Disease Site

Gynecologic [GY] Ovarian

Phase

I

Developmental Therapeutics

No

Primary Objective

To determine the maximum tolerated dose (MTD) and dose-limiting
toxicities of intraperitoneal (IP) bortezomib (BTZ) when administered
with intraperitoneal carboplatin in women with epithelial ovarian, fallopian tube, or primary peritoneal cancer that is persistent or recurrent and who have failed primary therapy and at least one second-line therapy.

To examine the safety of administering BTZ in combination with carboplatin by the IP route.

Patient Population

Women with epithelial ovarian, fallopian tube, or primary peritoneal cancer that is persistent or recurrent
and who have failed primary therapy and at least one second-line therapy.

Target Accrual

36

Patient Study Webpage

There is no available patient study webpage available for this trial at this time.